Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: Insights into the mechanism of termination

Circulation

Volumn 97, Issue 19, 1998, Pages 1935-1945

  Tai, Ching Tai ^a   Chen, Shih Ann ^a   Feng, An Ning ^a   Yu, Wen Chung ^b   Chen, Yi Jen ^a   Chang, Mau Song ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antiarrhythmia agents; Atrial flutter; Drugs

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; IBUTILIDE FUMARATE; PROPAFENONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART ATRIUM FLUTTER; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0032546642     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.19.1935     Document Type: Article

References (42)

1. Puech P, Latour H, Grolleau R. Le flutter et ses limites. Arch Mal Coeur. 1970;63:116-144.
2. Klein GJ, Guiraudon GM, Sharma AD, Milstein S. Demonstration of macroreentry and feasibility of operative therapy in the common type of atrial flutter. Am J Cardiol. 1986;57:587-591.
3. Olshansky B, Okumura K, Hess PG, Waldo AL. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol. 1990;16: 1639-1648.
4. Cosio FG, Lopez-Gil M, Goicolea A, Arribas F. Electrophysiologic studies in atrial flutter. Clin Cardiol. 1992;15:667-673.
5. Olgin JE, Kaiman JM, Fitzpatrick AP, Lesh MD. Role of right atrial endocardial structures as barriers to conduction during human type I atrial flutter: activation and entrainment mapping guided by intracardiac echocardiography. Circulation. 1995;92:1839-1848.
6. Kalman JM, Olgin JE, Saxon LA, Fisher WG, Lee RJ, Lesh MD. Activation and entrainment mapping defines the tricuspid annulus as the anterior barrier in typical atrial flutter. Circulation. 1996;94:398-406.
7. Bella PD, Marenzi G, Tondo C, Cardinale D, Giraldi F, Lauri G, Guazzi M. Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. Am J Cardiol. 1991;68:492-497.
8. Olshansky B, Wilber DJ, Hariman RA. Atrial flutter: update on the mechanism and treatment. PACE. 1992;15:2308-2336.
9. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation. 1986;74:197-204.
10. Feld GK, Venkatesh N, Singh BN. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. J Cardiovasc Pharmacol. 1988;11:573-580.
11. Inoue H, Yamashita T, Nozaki A, Sugimoto T. Effects of antiarrhythmia drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol. 1991;18:1098-1104.
12. Spinelli W, Huffman BF. Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res. 1989;65:1565-1579.
13. Ortiz J, Nozaki A, Shimizu A, Khrestian C, Rudy Y, Waldo AL. Mechanism of interruption of atrial flutter by moricizine: electrophysiological and multiplexing studies in the canine sterile pericarditis model of atrial flutter. Circulation. 1994;89:2860-2869.
14. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation. 1991;84:1831-1851.
15. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94: 1613-1621.
16. Folk RH, Pollak A, Singh SN, Friedrich T, for the Intravenous Dofetilide Investigators. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 1997;29:385-390.
17. Crijns HJGM, Van Gelder IC, Kingma JH, Dunselman PHJM, Gosselink ATM, Lie KI. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J. 1994;15:1403-1408.
18. Tai CT, Chen SA, Chiang CE, Lee SH, Ueng KC, Wen ZC, Huang JL, Chen YJ, Yu WC, Feng AN, Chiou CW, Chang MS. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter. Circulation. 1997;96:2601-2611.
19. Tai CT, Chen SA, Chiang CE, Lee SH, Ueng KC, Wen ZC, Chen YJ, Yu WC, Huang JL, Chiou CW, Chang MS. Electrophysiologic characteristics and radiofrequency catheter ablation in patients with clockwise atrial flutter. J Cardiovasc Electrophysiol. 1997;8:24-34.
20. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agents, and its enantiomers on isolated rabbit myocardium. Ear J Pharmacol. 1992;222:93-98.
21. Buchanan LV, Kabell G, Gibson JK. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J Cardiovasc Phamacol. 1995;25:539-544.
22. Buchanan LV, Kabell G, Turcotte UM, Brunden N, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol. 1992;19:256-263.
23. + current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99-108.
24. + current (Ikr) in AT-1 cells. Circulation. 1995;91:1799-1806.
25. Buchanan LV, Turcotte VM, Kabell G, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol. 1993;33:10-14.
26. Buchanan LV, LeMay RJ, Walters RR, Hsu CYL, Branden MN, Gibson JK. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol. 1996;7:113-119.
27. Cha Y, Wales A, Wolf P, Shahrokni S, Sawhney N, Feld GK. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy. J Cardiovasc Electrophysiol. 1996;7:809-827.
28. Grant AO. Propafenone: an effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol. 1996;7: 353-364.
29. Duan D, Fermini B, Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther. 1993;264: 1113-1123.
30. Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol. 1997;29:1190-1198.
31. Morady F, DiCarlo LA, Krol RB, Baerman JM, de Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol. 1986;7:148-157.
32. Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation. 1984;69:120-124.
33. Platou ES, Refsum H. Class III antiarrhythmic action in experimental atrial fibrillation and flutter in dogs. J Cardiovasc Pharmacol. 1982;4: 839-846.
34. Kinder C, Kall J, Kopp D, Rubenstein D, Burke M, Wilber D. Conduction properties of the inferior vena cava-tricuspid annular isthmus in patients with typical atrial flutter. J Cardiovasc Electrophysiol. 1997;8:727-737.
35. Guo GBF, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol. 1996;27:1083-1089.
36. Frame LH, Simson MB. Oscillations of conduction, action potential duration, and refractoriness: a mechanism for spontaneous termination of reentrant tachycardias. Circulation. 1988;78:1277-1287.
37. Frame KH, Rhee EK. Spontaneous termination of reentry after one cycle or short nonsustained runs: role of oscillations and excess dispersion of refractoriness. Circ Res. 1991;68:493-502.
38. Ortiz J, Igarashi I, Gonzalez HX, Laurita K, Rudy Y, Waldo AL. Mechanism of spontaneous termination of stable atrial flutter in the canine sterile pericarditis model. Circulation. 1993;88:1866-1877.
39. Cheng J, Karch MR, Scheinman MM. Electrophysiologic effects of ibutilide in patients with typical atrial flutter. PACE. 1997;20:1059.
40. Restivo M, Hegazy M, Caref EB, Avitable MJ, Assadi MA, El-Hamami M, Yin H, Piracha M, Brooks RR, El-Sherif N. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol. 1996;7:612-624.
41. Boyden PA, Graziano JN. Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol. 1993;4: 266-279.
42. Derakhchan K, Page P, Lambert C, Kus T. Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. J Pharmacol Exp Ther. 1994;270:47-54.